Form D · Biotechnology
Seranova Bio, Inc.
South San Francisco, CA · CIK 0001862032
Offering snapshot reported Feb 5, 2024 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 1, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2024 | Initial | $9,999,995 | No comparison | 4 | SEC filing |
| May 13, 2021 | Initial | $5,049,990 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-504369
Source: Form D, filed Feb 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leon Chen | Director |
| Beatrice Mc Queen | Executive |
| Sabah Oney | Director |
| Aaron Ring | Director, Executive |
| Damien Soghoian | Director, Executive |
| Jim Tananbaum | Director |
| Hui Tian | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
329 Oyster Point Boulevard 3 Fl
South San Francisco, CA, 94080
South San Francisco, CA, 94080